Anti-Human HLA-DRA Recombinant Antibody (1D09C3), PE (HM812127)

Name: Anti-Human HLA-DRA Recombinant Antibody (1D09C3), PE
Brand: abinScience
SKU: HM812127
Price: 154 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

50T
100T

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo	HM812127
Reactividad de especies	Human
Aplicaciones	FCM
Especie huésped	Mouse
Clonalidad	Monoclonal
Isotipo	IgG1, kappa
ID de clon	1D09C3
Conjugación	PE
Objetivo	HLA-DRA1, MHC class II antigen DRA, HLA-DRA, HLA class II histocompatibility antigen, DR alpha chain
Nivel de endotoxinas	Please contact with the lab for this information.
Productos asociados	Mouse IgG1, kappa Recombinant Isotype Control Antibody (MOPC-21), PE
Número de acceso	P01903
Forma	Liquid
Buffer de almacenamiento	0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300. Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.
Estabilidad y almacenamiento	Store at 4°C for 12 months. Protect from light. Do not freeze.
Fondo	HLA class II histocompatibility antigen, DR alpha chain (HLA-DRA) is a ~28 kDa protein. An alpha chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the beta chain HLA-DRB, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DR-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells. Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes. In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins. 1. Shams, H. et al. (2004) Journal of immunology (Baltimore, Md. : 1950) 173, 1966-77. PMID: 15265931 2. Röhn, TA. et al. (2004) Nature immunology 5, 909-18. PMID: 15322540 3. Deng, L. et al. (2007) Nature immunology 8, 398-408. PMID: 17334368 4. Kwok, WW. et al. (2012) Journal of immunology (Baltimore, Md. : 1950) 188, 2537-44. PMID: 22327072 5. Scally, SW. et al. (2013) The Journal of experimental medicine 210, 2569-82. PMID: 24190431 6. Muehling, LM. et al. (2016) Journal of immunology (Baltimore, Md. : 1950) 197, 3214-3224. PMID: 27591323 7. Galperin, M. et al. (2018) Science immunology 3. PMID: 29884618 8. Abelin, JG. et al. (2019) Immunity 51, 766-779.e17. PMID: 31495665 9. Stern, LJ. et al. (1994) Nature 368, 215-21. PMID: 8145819 10. Kropshofer, H. et al. (1997) Immunity 6, 293-302. PMID: 9075930
Nota	For flow cytometric staining, the suggested use of this reagent is 0.5 µg per million cells in 100 µL volume. It is recommended that the reagent be titrated for optimal performance for each application. For research use only.

Imágenes

Flow Cytometry

Flow-cytometry using PE anti-human HLA-DRA antibody. Daudi cells were stained with an irrelevant antibody (Green Histogram) or a PE anti-human HLA-DRA antibody monoclonal antibody (Catalog # HM812127, Red Histogram) at a concentration of 5 µg/ml for 30 mins at RT. After washing, cells analysed on a NovoCyte Flow Cytometer.

Referencias

Datasheet